section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, peripheral edema

Derm: flushing

EENT: hearing loss, nasal congestion, vision loss

GI: diarrhea, dyspepsia

GU: fertility, priapism

MS: back pain, limb pain, myalgia

Neuro: headache

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Cialis (for ED)

Renal Impairment

Hepatic Impairment

Cialis (for BPH or ED/BPH)

Renal Impairment

Hepatic Impairment

Adcirca, Alyq, and Tadliq (for PAH)

Renal Impairment

Hepatic Impairment

US Brand Names

Adcirca, Alyq, Cialis, Tadliq

Action

  • Increases cyclic guanosine monophosphate (cGMP) levels by inhibiting phosphodiesterase type 5, an enzyme responsible for the breakdown of cGMP. cGMP produces smooth muscle relaxation of the corpus cavernosum, which in turn promotes increased blood flow and subsequent erection. cGMP also leads to vasodilation of the pulmonary vasculature.
Therapeutic effects:
  • Cialis: Enhanced blood flow to the corpus cavernosum and erection sufficient to allow sexual intercourse.
  • Improved signs and symptoms of BPH.
  • Adcirca, Alyq, and Tadliq: Improved exercise tolerance in PAH.

Classifications

Therapeutic Classification: erectile dysfunction agents, vasodilators

Pharmacologic Classification: phosphodiesterase type 5 inhibitors

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Extensive tissue distribution; penetrates semen.

Protein Binding: 94%.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP3A4 isoenzyme system; metabolites are excreted in feces (61%) and urine (36%).

Half-Life: 17.5 hr.

Time/Action Profile

(vasodilation, improved erectile function)

ROUTEONSETPEAKDURATION
POrapid0.5–6 hr36



Patient/Family Teaching

Pronunciation

ta-DA-la-fil

Pill Image

tadalafil_195-8685.jpg